Atai extends cash runway into 2027 despite $39M fourth-quarter loss

The biopharmaceutical says its latest $59.2 million equity offering gives it financial stability through multiple clinical trial milestones.

The post Atai extends cash runway into 2027 despite $39M fourth-quarter loss appeared first on Green Market Report.